Key result
HEAL-LAA subset evaluates post-implantation OAC versus DAPT with fluoropolymer-coated LAAC devices.
Why the study?
The WATCHMAN FLX Pro LAAC device has a fluoropolymer coating designed to promote faster endothelialization, and outcomes of different discharge medication regimens after its implantation had not yet been examined.
Cohort
Answers are grounded in this paper and cite their sources.
Optimal antithrombotic regimen after fluoropolymer-coated LAAC remains undefined in this subset; leaves open questions for dedicated trials.
Oral anticoagulation (OAC) and dual antiplatelet therapy (DAPT) are the most prescribed regimens after left atrial appendage closure (LAAC). The WATCHMAN FLX Pro LAAC device is coated with a fluoropolymer designed to promote faster, more complete endothelization, but outcomes of different medications after implantation have not yet been examined. In this subset analysis of the HEAL-LAA post approval study, we compare outcomes in patients discharged on OAC vs. DAPT.
No takes yet. Share an insight, caveat, or question.
Alli et al. (2025) conducted a cohort in Left atrial appendage closure (LAAC) using a fluoropolymer-coated device (WATCHMAN FLX Pro). Oral anticoagulation (OAC) at discharge after fluoropolymer-coated LAAC device implantation vs. Dual antiplatelet therapy (DAPT) at discharge was evaluated. Oral anticoagulation versus dual antiplatelet therapy after fluoropolymer-coated LAAC device implantation was evaluated in a HEAL-LAA subset, though numerical outcomes were not provided in the text.
Synapse has enriched 10 related papers. Consider them for comparative context: